View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 03, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Chemours Co
Entity Central Index Key	0001627223
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		180,966,833

Interim Combined Statements of Operations (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Net sales	$ 1,508	$ 1,682	$ 2,871	$ 3,251
Cost of Goods Sold	1,282	1,311	2,393	2,551
Gross profit	226	371	478	700
Selling, general and administrative expense	157	183	324	356
Research and development expense	27	40	50	77
Employee separation and asset related charges, net	61	20	61	21
Total expenses	245	243	435	454
Equity in earnings of affiliates	8	7	11	12
Interest expense	(28)	0	(28)	0
Other income, net	21	20	14	29
(Loss) income before income taxes	(18)	155	40	287
Provision for income taxes	0	39	15	73
Net income	(18)	116	25	214
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net income	$ (18)	$ 116	$ 25	$ 214
Basic and diluted (loss) earnings per share	$ (0.10)	$ 0.64	$ 0.14	$ 1.18

Interim Combined Statements of Operations (Unaudited) Interim Combined Statements of Operations (Unaudited) (Parenthetical)	Jul. 01, 2015 shares
Subsequent Event [Member]
Stock issued, common stock	180,996,833

Interim Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net (loss) Income, pre-tax	$ (18)	$ 155	$ 40	$ 287
Net (loss) Income, tax	0	(39)	(15)	(73)
Net income	(18)	116	25	214
Foreign currency translation adjustment	(28)	0	(234)	0
Cumulative translation adjustment, tax	0	0	0	0
Cumulative translation adjustment, after-tax	(28)	0	(234)	0
Net (loss) gain, pre-tax	0	0	3	0
Net (loss) gain, tax	0	0	(1)	0
Net (loss) gain, after-tax	0	0	2	0
Effect of foreign exchange rates, pre-tax	(9)	0	23	0
Effect of foreign exchange rates, tax	2	0	(6)	0
Effect of foreign exchange rates, after-tax	(7)	0	17	0
Amortization of prior service cost, pre-tax	1	0	2	0
Amortization of prior service cost, tax	0	0	0	0
Amortization of prior service cost (benefit), after tax	1	0	2	0
Amortization of loss, pre-tax	3	0	7	0
Amortization of loss, tax	0	0	(1)	0
Amortization of loss, after tax	3	0	6	0
Pension benefit plans, net, pre-tax	(5)	0	35	0
Pension benefit plans, net, tax	2	0	(8)	0
Pension benefit plans, net, after-tax	(3)	0	27	0
Other comprehensive loss, pre-tax	(33)	0	(199)	0
Other comprehensive loss, tax	2	0	(8)	0
Other comprehensive loss, after-tax	(31)	0	(207)	0
Comprehensive (loss) income, pre-tax	(51)	155	(159)	287
Comprehensive (loss) income, tax	2	(39)	(23)	(73)
Comprehensive (loss) income, after-tax	(49)	116	(182)	214
Comprehensive income (loss) attributable to noncontrolling Interests, pre-tax	0	0	0	0
Comprehensive income (loss) attributable to noncontrolling Interests, tax	0	0	0	0
Comprehensive income (loss) attributable to noncontrolling Interests, after-tax	0	0	0	0
Comprehensive (loss) income attributable to Chemours, pre-tax	(51)	155	(159)	287
Comprehensive (loss) income attributable to Chemours, tax	2	(39)	(23)	(73)
Comprehensive (loss) income attributable to Chemours, after-tax	$ (49)	$ 116	$ (182)	$ 214

Interim Combined Balance Sheets - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Assets
Cash	$ 247	$ 0
Accounts and notes receivable - trade, net	1,038	846
Inventories	1,054	1,052
Prepaid expenses and other	105	43
Deferred income taxes	39	21
Total current assets	2,483	1,962
Property, plant and equipment	9,435	9,282
Less: Accumulated depreciation	(6,057)	(5,974)
Net property, plant and equipment	3,378	3,308
Goodwill	196	198
Intangible assets, net	12	11
Investments in affiliates	145	124
Other assets	471	375
Total assets	6,685	5,978
Liabilities and Equity
Accounts payable	919	1,046
Current maturities of long-term debt	16	0
Deferred income taxes	26	9
Dividend payable	100	0
Other accrued liabilities	380	352
Total current liabilities	1,441	1,407
Long-term debt	3,927	0
Other liabilities	485	464
Deferred income taxes	427	434
Total liabilities	6,280	2,305
Commitments and contingent liabilities
Stockholders' equity
DuPont Company Net Investment	836	3,650
Accumulated other comprehensive (loss) income	(435)	19
Total DuPont Company Net Investment	401	3,669
Noncontrolling interests	4	4
Total DuPont Company Net Investment and noncontrolling interests	405	3,673
Total liabilities, DuPont Company Net Investment and noncontrolling interests	$ 6,685	$ 5,978

Interim Consolidated Statements of DuPont Company Net Investment (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total DuPont Company Net Investment			$ 3,673	$ 3,217
Net income	$ (18)	$ 116	25	214
Establishment of pension plans, net and related accumulated other comprehensive income (loss)			110
Foreign currency translation adjustment	(28)	0	(234)	0
Pension, net of tax benefit of $8	(3)	0	27	0
Dividend declared			(100)
Non-cash debt exchange			(507)
Cash provided at separation by DuPont			247
Net transfers to (from) DuPont			(2,836)	431
Total DuPont Company Net Investment	405	3,862	405	3,862
Parent Company Net Investment [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total DuPont Company Net Investment			3,650	3,195
Net income			25	214
Establishment of pension plans, net and related accumulated other comprehensive income (loss)			357
Foreign currency translation adjustment			0
Pension, net of tax benefit of $8			0
Dividend declared			(100)
Non-cash debt exchange			(507)
Cash provided at separation by DuPont			247
Net transfers to (from) DuPont			(2,836)	431
Total DuPont Company Net Investment	836	3,840	836	3,840
Accumulated Other Comprehensive Income (Loss) [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total DuPont Company Net Investment			19	19
Net income			0	0
Establishment of pension plans, net and related accumulated other comprehensive income (loss)			(247)
Foreign currency translation adjustment			(234)
Pension, net of tax benefit of $8			27
Dividend declared			0
Non-cash debt exchange			0
Cash provided at separation by DuPont			0
Net transfers to (from) DuPont			0	0
Total DuPont Company Net Investment	(435)	19	(435)	19
Noncontrolling Interest [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total DuPont Company Net Investment			4	3
Net income			0	0
Establishment of pension plans, net and related accumulated other comprehensive income (loss)			0
Foreign currency translation adjustment			0
Pension, net of tax benefit of $8			0
Dividend declared			0
Non-cash debt exchange			0
Cash provided at separation by DuPont			0
Net transfers to (from) DuPont			0	0
Total DuPont Company Net Investment	$ 4	$ 3	$ 4	$ 3

Interim Consolidated Statements of DuPont Company Net Investment (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Stockholders' Equity [Abstract]
Net tax benefit	$ (2)	$ 0	$ 8	$ 0

Interim Combined Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net income	$ 25	$ 214
Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization	131	128
Other operating charges and credits, net	27	(1)
Equity in earnings of affiliates, net of dividends received of $0 and $1	(11)	(11)
Deferred tax benefit	(31)	(8)
Accounts and notes receivable - trade, net	(205)	(197)
Inventories and other operating assets	(68)	(25)
Accounts payable and other operating liabilities	(101)	(329)
Cash used for operating activities	(233)	(229)
Investing activities
Purchases of property, plant and equipment	(287)	(231)
Proceeds from sales of assets, net	8	29
Foreign exchange contract settlements	(12)	0
Investment in affiliates	(32)	0
Cash used for investing activities	(323)	(202)
Financing activities
Proceeds from issuance of debt, net	3,490	0
Debt issuance costs	(77)	0
Cash provided at separation by DuPont	247	0
Net transfers (to) from DuPont	(2,857)	431
Cash provided by financing activities	803	431
Increase in cash	247	0
Cash at beginning of period	0	0
Cash at end of period	247	0
SUPPLEMENTAL DISCLOSURE OF SIGNIFICANT NON-CASH INVESTING ACTIVITIES:
Change in property, plant and equipment included in accounts payable	$ (35)	$ 8

Interim Combined Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Statement of Cash Flows [Abstract]
Dividends received	$ 0	$ 1

Background and Description of the Business

6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Background and Description of the Business

The Chemours Company delivers customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide, refrigerants, industrial fluoropolymer resins, sodium cyanide, sulfuric acid and aniline. Chemours consists of three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions.

Chemours is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours' operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, the United Kingdom, France and Sweden. As of June 30, 2015, Chemours consists of 40 production facilities globally, six dedicated to Titanium Technologies, 20 dedicated to Fluoroproducts, 12 dedicated to Chemical Solutions and two that support multiple Chemours segments. At three of these sites, shared as of June 30, 2015 with other DuPont businesses, DuPont will continue its own manufacturing operations after separation, as well as contract manufacture for Chemours for the products currently produced by the Fluoroproducts segment at these sites.

Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on July 1, 2015 (the Distribution Date), DuPont completed the previously announced separation of the businesses comprising DuPont’s Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The separation was completed by way of a distribution of all of the then outstanding shares of common stock of Chemours through a dividend in kind of Chemours’ common stock (par value $0.01) to holders of DuPont common stock (par value $0.30) as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the distribution).

On the Distribution Date, each holder of DuPont's common stock received one share of Chemours' common stock for every five shares of DuPont's common stock held on the Record Date. The spin-off was completed pursuant to a Separation Agreement and other agreements with DuPont related to the spin-off, including an Employee Matters Agreement, a Tax Matters Agreement, a Transition Services Agreement and an Intellectual Property Cross-License Agreement, each of which was filed as an exhibit to our Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (SEC) on July 1, 2015. These agreements govern the relationship among Chemours and DuPont following the spin-off and provide for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours. For a discussion of each agreement, see the section entitled “Certain Relationships and Related Party Transactions — Agreements with DuPont Related to the Spin-Off” in our Information Statement included in our Registration Statement on Form 10, as amended, filed with the SEC on June 5, 2015 (Registration Statement).

The Registration Statement was declared effective by the SEC on June 17, 2015, and Chemours' common stock began “regular-way” trading on the NYSE on July 1, 2015 under the symbol CC.

Unless the context otherwise requires, references in these Notes to the Consolidated Financial Statements to "we," "us," "our," "Chemours" and the "Company" refer to The Chemours Company and its consolidated subsidiaries after giving effect to the distribution.

Basis of Presentation

The accompanying Interim Consolidated Financial Statements present, on a historical cost basis, the consolidated assets, liabilities, revenues and expenses related to Chemours, a wholly-owned subsidiary of E. I. du Pont de Nemours and Company (DuPont) as of June 30, 2015. Chemours did not operate as a separate, stand-alone entity for the full period covered by these financial statements during the six months ended June 30, 2015. Chemours operations were included in DuPont's financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. Consequently, stand-alone financial statements have not been historically prepared for Chemours. The accompanying Interim Consolidated Financial Statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. Prior to January 1, 2015, aside from a Japanese entity that is a dual-resident for U.S. income tax purposes, there was no direct ownership relationship among all the other various legal entities comprising Chemours. Accordingly, DuPont and its subsidiaries’ net investments in these operations is shown in lieu of Stockholder’s Equity in the Interim Consolidated Financial Statements. The Interim Consolidated Financial Statements include the historical operations, assets and liabilities of the legal entities that are considered to comprise the Chemours business, including certain environmental remediation and litigation obligations for which Chemours will indemnify DuPont.

All of the allocations and estimates in the Interim Consolidated Financial Statements are based on assumptions that management believes are reasonable. However, the Interim Consolidated Financial Statements included herein may not be indicative of the financial position, results of operations and cash flows of Chemours in the future or if Chemours had been a separate, stand-alone entity during the periods presented.

The accompanying Interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Certain reclassifications of prior year's data have been made to conform to current period presentation. Results for interim periods should not be considered indicative of results for a full year. These Interim Consolidated Financial Statements do not represent complete financial statements and should be read in conjunction with the audited Combined Financial Statements for the years ended December 31, 2014, 2013 and 2012, collectively referred to herein as the “Annual Combined Financial Statements” in our Information Statement included in our Registration Statement. Unless otherwise stated, references to years and three and six month periods relate to Chemours' fiscal years and three and six month periods. The notes that follow are an integral part of the Interim Consolidated Financial Statements.

The net transfers from DuPont on the Interim Consolidated Statements of DuPont Company Net Investment include a non-cash contribution from DuPont of $93 for the six months ended June 30, 2015. These non-cash contributions occurred as physical separation activities occurred at shared production facilities in the United States. It was determined that assets previously managed by other DuPont businesses would be transferred to and managed by Chemours.

During 2015, the Company began transitioning to the new Chemours structure; however, the final structure was not in place until the end of the second quarter of 2015. The Company’s structure changed until the time of separation and distribution as Chemours legal entities were brought into direct chains of ownership. No provision has been made for income taxes on unremitted earnings of subsidiaries and affiliates because earnings of the foreign subsidiaries are deemed to be indefinitely reinvested, which is consistent with DuPont's assertion.

Dividend Declared: On June 9, 2015, our Board of Directors, consisting of DuPont employees, declared a dividend of $100 to be paid on September 11, 2015 to our stockholders of record on August 3, 2015. We recorded this dividend payable in our balance sheet at the time of declaration.

Pro Forma Earnings per Share: Pro forma earnings per share (EPS) was calculated based on 180,996,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015. The same number of shares was used to calculate basic and diluted earnings per share since no Chemours equity awards were outstanding prior to the spin-off.



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015		2014
Net (loss) income attributable to Chemours (as reported)	$	(18	)	$	116		$	25	$	214
Historical pro forma earnings per share data
(Loss) earnings per share attributable to Chemours
Basic and diluted	(0.10		)	0.64		¹	0.14		1.18		¹
Weighted average number of shares outstanding
Basic and diluted	180,996,833			180,996,833			180,996,833		180,996,833

¹ The historical pro forma EPS calculation does not reflect interest expense on approximately $4,003 of debt we issued during the second quarter of 2015 in connection with the spin-off. See Note 14 for additional information.

Basis of Presentation

6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Background and Description of the Business

The Registration Statement was declared effective by the SEC on June 17, 2015, and Chemours' common stock began “regular-way” trading on the NYSE on July 1, 2015 under the symbol CC.

Basis of Presentation



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015		2014
Net (loss) income attributable to Chemours (as reported)	$	(18	)	$	116		$	25	$	214
Historical pro forma earnings per share data
(Loss) earnings per share attributable to Chemours
Basic and diluted	(0.10		)	0.64		¹	0.14		1.18		¹
Weighted average number of shares outstanding
Basic and diluted	180,996,833			180,996,833			180,996,833		180,996,833

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The significant accounting policies are described in the Annual Combined Financial Statements in our Information Statement included in our Registration Statement. The following significant accounting policies have been updated during 2015. Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: 1) extension of the parent (U.S. dollar functional currency) and 2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed. During the periods covered by the Interim Consolidated Financial Statements, part of the Chemours business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, except for inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, which are remeasured at historical rates. Foreign currency-denominated income and expenses are remeasured at average exchange rates in effect during the period, except for expenses related to balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollar at end-of-period exchange rates and the resulting translation adjustments are reported as a component of accumulated other comprehensive (loss) income in equity. Assets and liabilities denominated in other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars and the resulting exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into U.S. dollars at average exchange rates in effect during the period. Beginning in 2015, when the Performance Chemicals operations were legally and operationally separated within DuPont in anticipation of the spin-off, some of the resulting newly created Chemours foreign entities set their local currency as the functional currency. Employee Benefits Certain of Chemours’ employees participate in defined benefit pension and other post-employment benefit plans (the Plans) sponsored by DuPont and accounted for by DuPont in accordance with accounting guidance for defined benefit pension and other post-employment benefit plans. Substantially all expenses related to these plans were allocated in shared entities and reported within costs of goods sold, selling, general and administrative expenses and research and development expense in the Interim Consolidated Statements of Operations. Chemours considered all plans to be part of a multi-employer plan with DuPont prior to January 1, 2015. In connection with the spin-off, Chemours retained the existing Netherlands pension plan and an agreement was executed in 2015 to ensure continuance of the plan for both DuPont and Chemours employees and retirees. As a result of that agreement, Chemours now accounts for the Netherlands plan as a multiple employer plan. Additionally, in 2015, Chemours formed a new pension plan in Taiwan that mirrors the plan historically operated by DuPont in Taiwan. The new Taiwan plan is accounted for under the single employer method. For both of these plans, the assets, liabilities and expenses applicable to Chemours are included in these Interim Consolidated Financial Statements (See Note 17 for further information). Derivatives Prior to 2015, Chemours participated in DuPont’s foreign currency hedging program to reduce earnings and cash flow volatility associated with foreign currency exchange rate changes. DuPont formally documented the hedge relationships, including identification of the hedging instruments and the hedged items, the risk management objectives and strategies for undertaking the hedge transactions and the methodologies used to assess effectiveness and measure ineffectiveness. Realized gains and losses on derivative instruments of DuPont were allocated by DuPont to Chemours based on projected exposure. Chemours recognized its allocable share of the gains and losses on DuPont’s derivative financial instruments in earnings when the forecasted sales occurred for foreign currency hedges. The foreign currency hedges qualified as cash flow hedges, and the realized gains recognized in earnings were less than $1 for the three and six months ended June 30, 2014. Chemours’ participation in this program terminated as of January 1, 2015. Beginning in February 2015, Chemours began entering into forward currency exchange contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring net monetary assets that Chemours holds which are denominated in non-functional currencies. These derivatives are stand-alone and are not part of a cash flow hedge or fair value hedge program, and have not been designated as a hedge. The derivative assets and liabilities are reported on a gross basis in the Interim Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Interim Consolidated Statements of Operations during the period in which they occurred. Chemours does not hold or issue financial instruments for speculative or trading purposes. Fair Value Measurement Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical asset and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours uses the following valuation techniques to measure fair value for its assets and liabilities: (a) Level 1—Quoted market prices in active markets for identical assets and liabilities (b) Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and (c) Level 3—Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability. Recent Accounting Pronouncements In May 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-07, "Fair Value Measurement (Topic 820) - Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share or its Equivalent." This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The guidance is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours is currently evaluating the impact of adopting this guidance. In April 2015, the FASB issued ASU No. 2015-03, “Interest — Imputation of Interest (Subtopic 835-30),” which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of the debt, consistent with debt discounts. The ASU is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. Chemours adopted this guidance for the quarter ending June 30, 2015. The adoption of this standard has no impact on Chemours’ results of operations or cash flows. Due to the accounting change described above, Chemours recorded debt issuance costs incurred for the issuance of its senior secured term loans and senior unsecured notes as a reduction of the liability on the Interim Consolidated Balance Sheets. See Note 14 for additional information. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments under the new guidance modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The ASU is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. A reporting entity also may apply the amendments retrospectively. Chemours is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In May 2014, the FASB and the International Accounting Standards Board (IASB) jointly issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards (IFRS). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The ASU is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date). In July 2015, the FASB approved a deferral of the effective date of the ASU to provide entities with adequate time to effectively implement the new revenue standard and adoption as of the original effective date is permitted. The Company is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” amending existing requirements for reporting discontinued operations. Under the new guidance, discontinued operations reporting will be limited to disposal transactions that represent strategic shifts having a major effect on operations and financial results. The amended guidance also enhances disclosures and requires assets and liabilities of a discontinued operation to be classified as such for all periods presented in the financial statements. Public entities will apply the amended guidance prospectively to all disposals occurring within annual periods beginning on or after December 15, 2014 and interim periods within those years. Chemours adopted this standard on January 1, 2015. Due to the change in requirements for reporting discontinued operations described above, presentation and disclosures of future disposal transactions after adoption may be different than under current standards.

Relationship with DuPont and Related Entities

6 Months Ended

Jun. 30, 2015

Relationship with DuPont and Related Entities

Historically, Chemours has been managed and operated in the normal course of business with other affiliates of DuPont. Accordingly, certain shared costs have been allocated to Chemours and reflected as expenses in the stand-alone Interim Consolidated Financial Statements. Management of DuPont and Chemours consider the allocation methodologies used to be reasonable and appropriate reflections of the historical DuPont expenses attributable to Chemours for purposes of the stand-alone financial statements. The expenses reflected in the Consolidated Financial Statements may not be indicative of expenses that will be incurred by Chemours in the future. All related party transactions approximate market prices.

(a) Related Party Purchases and Sales

Throughout the period covered by the Interim Consolidated Financial Statements, Chemours sold finished goods to DuPont and its non-Chemours businesses.

Related party sales to other DuPont businesses include the following amounts:



Selling Segment	Three Months Ended June 30,				Six Months Ended June 30,
Selling Segment	2015		2014		2015		2014
Titanium Technologies	$	1	$	—	$	2	$	—
Fluoroproducts	16		12		34		24
Chemical Solutions	11		22		21		41
Total	$	28	$	34	$	57	$	65

Chemours' Fluoroproducts segment purchased byproducts in the amount of $1 and $2 from other DuPont businesses during the three and six months ended June 30, 2015, respectively. For the three and six months ended June 30, 2014, Chemours' Chemical Solutions segment purchased byproducts in the amount of $1 from other DuPont businesses.

(b) Leveraged Services and Corporate Costs

DuPont incurred significant corporate costs for services provided to Chemours as well as other DuPont businesses. These costs included expenses for information systems, accounting, other financial services such as treasury and audit, purchasing, human resources, legal, facilities, engineering, corporate research and development, corporate stewardship, marketing and business analysis support.

A portion of these costs benefited multiple or all DuPont businesses, including Chemours, and are allocated to Chemours and its reportable segments using methods based on proportionate formulas involving total costs or other various allocation methods that management considered consistent and reasonable. Other Chemours corporate costs are not allocated to the reportable segments and are reported in Corporate and Other.

The allocated leveraged functional service expenses and general corporate expenses included in the Interim Consolidated Statements of Operations were $116 and $238 for the three and six months ended June 30, 2015, respectively, and $131 and $257 for the three and six months ended June 30, 2014, respectively. Allocated leveraged functional service expenses and general corporate expenses were recorded in the Interim Consolidated Statements of Operations within the following captions:



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Selling, general and administrative expense	$	100	$	110	$	205	$	213
Research and development expense	6		13		10		27
Cost of goods sold	10		8		23		17
Total	$	116	$	131	$	238	$	257

At June 30, 2015, Chemours has manufacturing operations at 40 production facilities globally. Chemours shares 14 of these production facilities with DuPont’s other non-Chemours manufacturing operations. Additionally, Chemours shares warehouse, sales centers, office space and research and development facilities with other DuPont businesses. The property, plant and equipment primarily or exclusively used by Chemours for these shared locations are included in the Interim Consolidated Balance Sheets.

The full historical cost, accumulated depreciation and depreciation expense of property, plant and equipment primarily or exclusively used by Chemours at shared manufacturing plant sites and other facilities where Chemours is the primary or exclusive user of the assets have been included in the Interim Consolidated Balance Sheets and Statements of Operations.

(d) Cash Management and Financing

For the periods presented, Chemours participated in DuPont’s centralized cash management and financing programs. Disbursements were made through centralized accounts payable systems which are operated by DuPont. Cash receipts were transferred to centralized accounts, also maintained by DuPont. As cash was disbursed and received by DuPont, it was accounted for by Chemours through DuPont Company Net Investment. At June 30, 2015, immediately prior to our separation from DuPont, Chemours had approximately $247 of cash, which was in excess of the target $200 of cash pursuant to the Separation Agreement. During the third quarter of 2015, cash, working capital and other accounts will be reconciled with DuPont and net settlement of any amounts due to DuPont will be completed pursuant to the Separation Agreement.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Research and Development Expense	6 Months Ended
Research and Development Expense	Jun. 30, 2015
Research and Development [Abstract]
Research and Development Expense	Research and Development Expense Research and development expense directly incurred by Chemours was $21 and $40 for the three and six months ended June 30, 2015, respectively, and $27 and $50 for the three and six months ended June 30, 2014, respectively. Research and development expense also includes $6 and $10 for the three and six months ended June 30, 2015, respectively, and $13 and $27 for the three and six months ended June 30, 2014, respectively, representing an assignment of costs associated primarily with DuPont’s Corporate Central Research and Development long-term research activities. This assignment was based on the cost of research projects for which Chemours was determined to be the sponsor or co-sponsor. All research services provided by DuPont’s Central Research and Development to Chemours are specifically requested by Chemours, covered by service-level agreements and billed based on usage.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

Employee Separation and Asset Related Charges, Net

6 Months Ended

Jun. 30, 2015

Restructuring Charges [Abstract]

Employee Separation and Asset Related Charges, Net

2015 Restructuring Program

In 2015, in light of continued weakness in the global titanium dioxide market cycle and continued foreign currency impacts due to the strengthening of the U.S. dollar, Chemours accelerated implementation of its near-term priorities to drive operational and functional effectiveness to achieve both manufacturing and selling, general and administrative fixed cost improvements. Accordingly, in the second quarter of 2015, Chemours implemented a restructuring plan to reduce and simplify its cost structure. As a result, in June 2015 a pre-tax charge of $61 was recorded for employee separation costs. The actions associated with this charge and all related payments are expected to be substantially complete by the end of 2016 and will result in future cash payments of about $53 related to severance and benefits.

2014 Restructuring Program

During 2014, Chemours implemented a restructuring plan to increase productivity and recorded a pre-tax charge of $19 in employee separation and asset related charges, net in the Consolidated Statements of Operations related to this initiative. The charge consisted of $16 related to employee separation costs and $3 for asset shut-down costs. The actions associated with this charge and all related payments are expected to be substantially complete by December 31, 2015.

The charges related to the 2015 and 2014 restructuring programs impacted segment earnings as follows:



	Three and Six Months Ended June 30,
	2015			2014
2015 Restructuring Plan
Titanium Technologies	$	23		$	—
Fluoroproducts	25			—
Chemical Solutions	13			—
Total	$	61	¹	$	—

2014 Restructuring Plan
Titanium Technologies	$	—		$	3
Fluoroproducts	—			16
Total	$	—		$	19

¹ Includes approximately $13 related to Corporate overhead functions that was allocated to our segments.

The following table shows the change in the liability account balance associated with our restructuring plans and activity related to the 2015 and 2014 restructuring programs.



	Employee Separation Costs
	2015 Restructuring Plan			2014 Restructuring Plan
Balance as of December 31, 2014	$	—		$	12
Charges to income for the six months ended June 30, 2015	61			—
Charges to liability accounts:
Payments ¹	(8		)	(9		)
Net currency translation adjustment	—			—
Balance as of June 30, 2015	$	53		$	3

¹Payments related to the 2015 restructuring plan were made in the second quarter of 2015. For the 2014 plan, payments of $2 and $7 were made in the first and second quarters of 2015, respectively.

Other Income, Net

6 Months Ended

Jun. 30, 2015

Other Income and Expenses [Abstract]

Other Income, Net



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Leasing, contract services and miscellaneous income ¹	$	—	$	2	$	4	$	5
Royalty income²	2		4		7		9
Gain on sale of assets and businesses ³	—		9		—		11
Exchange gains (losses), net ⁴	19		5		3		4
Total other income, net	$	21	$	20	$	14	$	29

¹Leasing, contract services and miscellaneous income includes accrued interest related to unrecognized tax benefits.

² Royalty income is primarily for technology and trademark licensing.

³Gain on sale of assets and businesses primarily relates to a sale of assets in the Fluoroproducts segment.

⁴Chemours uses foreign currency exchange derivatives to offset its net exposure, by currency, related to its non-functional currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in non-functional currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The pre-tax exchange gains are recorded in other income, net and the related tax impact is recorded in provision for income taxes on Chemours' Interim Consolidated Statements of Operations. The $3 net exchange gain for the six months ended June 30, 2015 includes a $9 pre-tax exchange loss on non-functional monetary assets and liabilities as a result of the strengthening of the U.S. dollar against the Euro, Japanese yen and Brazilian real, and a gain on derivatives of $12. The $19 net exchange gain for the three months ended June 30, 2015 includes $4 pre-tax exchange loss on non-functional monetary assets and liabilities as a result of the strengthening of the U.S. dollar against the Euro, Japanese yen and Brazilian real, and a gain on derivatives of $23.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Chemours recorded a tax benefit of $0 and a provision of $15 for the three and six months ended June 30, 2015, respectively, and a provision of $39 and $73 for the three and six months ended June 30, 2014, respectively. Each year, DuPont and/or its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions. These tax returns are subject to examination and possible challenge by the taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by DuPont. As a result, income tax uncertainties are recognized in Chemours’ Interim Consolidated Financial Statements in accordance with accounting for income taxes, when applicable. It is reasonably possible that changes to Chemours' global unrecognized tax benefits could be significant; however, due to the uncertainty regarding the timing of completion of audits and possible outcomes, a current estimate of the range of such changes that may occur within the next twelve months cannot be made. For the three and six months ended June 30, 2015, Chemours asserted that all unremitted foreign earnings were permanently reinvested, which is consistent with DuPont's assertion. As such, applicable U.S. federal income taxes and foreign withholding taxes have not been provided on the accumulated earnings of foreign subsidiaries at June 30, 2015. In connection with the spin-off from DuPont, which was effective July 1, 2015, the Company continues to assess its jurisdictional cash needs, cash repatriation options, other available sources of cash, and the related permanent reinvestment assertions. If the Company were to change the permanent reinvestment assertions, based upon different scenarios, this could result in a potential estimated income tax expense of up to $160. During the preparation of the second quarter interim financial statements, Chemours identified and corrected an error related to deferred taxes associated with pension plans established in the first quarter of 2015. The adjustment relates to the first quarter 2015, and resulted in a decrease in deferred tax assets of $23 and an increase in deferred tax liabilities of $49 with a corresponding reduction in the DuPont Company Net Investment of $72 at June 30, 2015. The error was not material to Chemours’ current or previously reported financial statements.

Accounts and Notes Receivable - Trade, Net

6 Months Ended

Jun. 30, 2015

Receivables [Abstract]

Accounts and Notes Receivable - Trade, Net

Accounts and Notes Receivable – Trade, Net



	June 30, 2015		December 31, 2014
Accounts receivable—trade, net ¹	$	896	$	746
VAT, GST and other taxes ²	86		62
Advances and deposits	14		15
Leases receivable—current	12		12
Notes receivable—trade ³	30		11
Total	$	1,038	$	846

¹Accounts receivable – trade is net of allowances of $4 and $4 as of June 30, 2015 and December 31, 2014, respectively. Allowances are equal to the estimated uncollectible amounts.

²Value Added Tax (VAT) and Goods and Services Tax (GST) receivables are generally recorded at the legal entity level and allocated to Chemours within shared legal entities.

³Notes receivable – trade primarily consists of $13 of derivative assets and loan receivables with terms of one year or less which are primarily concentrated in China. As of June 30, 2015, there were no past due notes receivable, nor were there any impairments related to current loan agreements.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was less than $1 for the three and six months ended June 30, 2015. Bad debt expense was less than $1 for the three and six months ended June 30, 2014.

Direct Financing Leases

At two of its facilities in the U.S. (Borderland and Morses Mill), Chemours has constructed fixed assets on land that it leases from third parties. Management has analyzed these arrangements and determined these assets represent a direct financing lease, whereby Chemours is the lessor of this equipment. Chemours has recorded leases receivable of $143 and $149 at June 30, 2015 and December 31, 2014 respectively, which represent the balance of the minimum future lease payments receivable. The current portion of leases receivable is included in accounts and notes receivable - trade, net, as shown above. The long-term portion of leases receivable are included in other assets, as shown in Note 13. Management has evaluated the realizable value of these leased assets and determined no impairment existed at June 30, 2015 or December 31, 2014. There is no estimated future residual value of these leased assets.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

6 Months Ended

Jun. 30, 2015

Inventory, Net [Abstract]

Inventories



	June 30, 2015			December 31, 2014
Finished products	$	703		$	611
Semi-finished products	160			173
Raw materials, stores and supplies	437			521
Subtotal	1,300			1,305
Adjustment of inventories to a last-in, first-out (LIFO) basis	(246		)	(253		)
Total	$	1,054		$	1,052

Inventory values, before LIFO adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all of the U.S. locations, which comprised $652 and $684 or 50% and 52% of inventories before the LIFO adjustments at June 30, 2015 and December 31, 2014, respectively. The remainder of inventory held in international locations and certain U.S. locations is valued under the average cost method.

Property, Plant, and Equipment	6 Months Ended
Property, Plant, and Equipment	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Depreciation expense amounted to $66 and $129 for the three and six months ended June 30, 2015, respectively and $64 and $127 for the three and six months ended June 30, 2014, respectively. Property, plant and equipment includes gross assets under capital leases of $7 at June 30, 2015 and $6 at December 31, 2014.

Intangible Assets, Net

6 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:



	June 30, 2015							December 31, 2014
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer lists	$	19	$	(17	)	$	2	$	19	$	(16	)	$	3
Patents	20		(17		)	3		20		(16		)	4
Purchased trademarks	18		(14		)	4		18		(14		)	4
Purchased and licensed technology	20		(17		)	3		17		(17		)	—
Total	$	77	$	(65	)	$	12	$	74	$	(63	)	$	11

The aggregate pre-tax amortization expense for definite-lived intangible assets was $1 and $2 for the three and six months ended June 30, 2015 and less than $1 and $1 for the three and six months ended June 30, 2014, respectively. Definite-lived intangible assets are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. There are no material indefinite-lived intangible assets.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Other Assets

6 Months Ended

Jun. 30, 2015

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Assets



	June 30, 2015		December 31, 2014
Leases receivable - non-current¹	$	131	$	137
Capitalized repair and maintenance costs	149		185
Pension assets ²	115		—
Advances and deposits	14		17
Deferred income taxes - non-current	23		9
Miscellaneous ³	39		27
Total	$	471	$	375

¹Leases receivable includes direct financing type leases of property at two locations. See Note 9 for further information.

²Pension assets represent pension plans commencing in 2015 covering Chemours' employees in the Netherlands and Taiwan. See Note 17 for further information.

³Miscellaneous includes prepaid expenses for royalty fees, vendor supply agreements and taxes other than income taxes, deferred financing fees related to the Revolving Credit Facility of $20, as well as capitalized expenses for the preparation of future landfill cells at Titanium Technologies’ New Johnsonville plant site.

Debt

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Debt

In conjunction with Chemours' separation from DuPont, Chemours entered into approximately $4,003 of financing transactions on May 12, 2015. Long-term debt, net of an unamortized discount on the Term Loan Facility of $7, was comprised of the following at June 30, 2015:



	June 30, 2015
Long-term debt:
Senior secured term loan, net of issue discount	$	1,493
Senior unsecured notes:
6.625%, due May 2023	1,350
7.00%, due May 2025	750
6.125%, due May 2023 (€360)	403
Other	3
Total	3,999
Less: Unamortized debt issuance costs	56
Less: Current maturities	16
Total long-term debt	$	3,927

Senior Secured Credit Facilities

On May 12, 2015, Chemours entered into a credit agreement that provides for a seven-year senior secured term loan (the Term Loan Facility) in a principal amount of $1,500, repayable in equal quarterly installments at a rate of one percent of the original principal amount per year, with the balance payable on the final maturity date. Beginning in the third quarter of 2015, Chemours will make principal payments of $8 in total during 2015 related to this obligation. Additionally, the credit agreement provides for an incremental term loan of up to $700 plus an additional amount, so long as, on a pro forma basis (including the full amount of such incremental term loan borrowings and/or increased commitments under the Revolving Credit Facility) after giving effect to any such increases, our senior secured net leverage ratio does not exceed 1.50 to 1.00. The Term Loan Facility was issued with a $7 original issue discount and bears variable interest rate subject to a floor of 3.75%. The proceeds from the Term Loan Facility were used to fund a portion of the distribution to DuPont, along with related fees and expenses.

Chemours’ obligations under the senior secured credit facilities are guaranteed on a senior secured basis by all of its material domestic subsidiaries, subject to certain agreed upon exceptions. The obligations under the senior secured credit facilities are also, subject to certain agreed upon exceptions, secured by a first priority lien on substantially all of Chemours and its material wholly-owned domestic subsidiaries’ assets, including 100% of the stock of domestic subsidiaries and 65% of the stock of certain foreign subsidiaries.

The credit agreement also provides for a five-year $1,000 senior secured revolving credit facility (the Revolving Credit Facility). The proceeds of any loans made under the Revolving Credit Facility can be used for capital expenditures, acquisitions, working capital needs and other general corporate purposes. We had no borrowings outstanding under our Revolving Credit Facility at June 30, 2015, and we had $126 in letters of credit issued and outstanding under this facility. The Revolving Credit Facility bears variable interest of a range based on our total net leverage ratio between (a) 0.50% and 1.25% for base rate loans and (b) 1.50% and 2.25% for LIBOR loans. The applicable margin was 1.00% for base rate loans and 2.00% for LIBOR loans as of June 30, 2015. In addition, we are required to pay a commitment fee on the average daily unused amount of the Revolving Credit Facility at a rate based on its total net leverage ratio, between 0.20% and 0.35%. Commitment fees are currently assessed at a rate of 0.30%.

The credit agreement contains financial covenants which, solely with respect to the Revolving Credit Facility, require Chemours (i) not to exceed a maximum total net leverage ratio and, (ii) unless Chemours has achieved an investment grade rating as specified in the credit agreement, to maintain a minimum interest coverage ratio of greater than or equal to 3.00 to 1.00. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours and its subsidiaries' ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default.

Senior Unsecured Notes

On May 12, 2015, Chemours issued senior unsecured notes (the Notes) with an aggregate principal of approximately $2,503 in a private placement subject to a registration rights arrangement.

All of the notes, including the 2023 notes with an aggregate principal amount of $1,350, the 2025 notes with an aggregate principal amount of $750 and the 2023 Euro notes with an aggregate principal amount of €360 ($403), require payment of principal at maturity and interest semi-annually in cash in arrears on May 15 and November 15 of each year.

The proceeds from the Notes were used to fund the cash and in-kind distributions to DuPont and to pay related fees and expenses. The in-kind distribution to DuPont of $507 aggregate principal amount of Chemours 2025 Notes were exchanged by DuPont with third parties for certain DuPont notes.

Chemours is required to register the Notes with the SEC within 465 days after the original issue date. If Chemours fails to do so, it would be required to pay additional interest at a rate of 0.25% for the first 90 days following a registration default and additional 0.25% per annum with respect to each subsequent 90-day period, up to a maximum rate of 0.50%, until the registration requirements are met. Application is also expected to be made to the Irish Stock Exchange for the approval of listing particulars in relation to the Euro notes prior to the first anniversary of the issue date of the Euro notes.

Maturities

There are no debt maturities in each of the next seven years, except, in accordance with the credit agreement, Chemours has required principal payments related to the Term Loan Facility of $8 in 2015 and $15 each year from 2016 to 2021. Debt maturities related to the Term Loan Facility and the Notes in 2022 and beyond will be $3,905.

Debt Fair Value

The fair values of the Term Loan Facility, the 2023 notes, the 2025 notes and the 2023 Euro notes at June 30, 2015 were $1,491, $1,313, $728 and $387, respectively. The estimated fair values of the Term Loan Facility and the Notes are based on quotes received from third party brokers, and are classified as Level 2 in the fair value hierarchy.

Commitments and Contingent Liabilities	6 Months Ended
Commitments and Contingent Liabilities	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	Commitments and Contingent Liabilities (a) Guarantees Obligations for Equity Affiliates & Others Chemours, through DuPont, has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates, customers, suppliers and other affiliated companies. At June 30, 2015 and December 31, 2014, Chemours had directly guaranteed $2 and $41 of such obligations, respectively. This represents the maximum potential amount of future (undiscounted) payments that Chemours could be required to make under the guarantees. Chemours would be required to perform on these guarantees in the event of default by the guaranteed party. No amounts were accrued at June 30, 2015 and December 31, 2014. Chemours assesses the payment and performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used. (b) Litigation In addition to the matters discussed below, Chemours, by virtue of its status as a subsidiary of DuPont prior to the distribution, is subject to various pending legal proceedings arising out of the normal course of the Chemours business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. While management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours' consolidated financial position, results of operations or liquidity. With respect to the litigation matters discussed below, management's estimate of the probability of loss in excess of the amounts accrued, if any, is addressed individually for each matter. Asbestos At June 30, 2015, there were approximately 2,500 lawsuits pending against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. Most of the actions were brought by contractors who worked at sites between 1950 and the 1990s. A small number of cases involve similar allegations by DuPont employees. A limited number of the cases were brought by household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products. At June 30, 2015 and December 31, 2014, Chemours had an accrual of $38 related to this matter. Management believes that the likelihood is remote that Chemours would incur losses in excess of the amounts accrued in connection with this matter. PFOA Prior to the fourth quarter of 2014, Chemours used PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) as a processing aid to manufacture some fluoropolymer resins at various sites around the world including its Washington Works plant in West Virginia. Chemours had accruals of $14 related to the PFOA matters discussed below at June 30, 2015 and December 31, 2014. The accruals include charges related to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain company sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national Provisional Health Advisory. Drinking Water Actions In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water. DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community health project. Chemours, through DuPont, funded a series of health studies which were completed in October 2012 by an independent science panel of experts (the C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis and diagnosed high cholesterol. In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. Through DuPont, Chemours is obligated to fund up to $235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, Chemours, through DuPont, put $1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed Director of Medical Monitoring has established the program to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing has begun and associated payments to service providers are being disbursed from the escrow account. As of June 30, 2015, less than $1 had been disbursed from the escrow account related to medical monitoring. In addition, under the settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts, including the Little Hocking Water Association (LHWA) and private well users. Class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. At June 30, 2015 and March 31, 2015, there were approximately 3,500 lawsuits filed in various federal and state courts in Ohio and West Virginia. The number of lawsuits pending at June 30, 2015 reflects the filing of about 50 additional cases and plaintiffs' voluntary dismissal of about 40 cases during the second quarter of 2015. In accordance with a stipulation reached in the third quarter of 2014 and other court procedures, these lawsuits have been or will be served and consolidated in multi-district litigation in Ohio federal court (MDL). Based on the information currently available to the company, the majority of the lawsuits allege personal injury claims associated with high cholesterol and thyroid disease from exposure to PFOA in drinking water. There are 37 lawsuits alleging wrongful death. In the third quarter of 2014, six plaintiffs from the MDL were selected for individual trial. The first trial is scheduled to begin in September 2015, and the second in November 2015. Chemours, through DuPont, denies the allegations in these lawsuits and is defending itself vigorously. No claims have been settled or resolved during the periods presented. Additional Actions An Ohio action brought by the LHWA is ongoing. In addition to general claims of PFOA contamination of drinking water, the action claims “imminent and substantial endangerment to health and or the environment” under the Resource Conservation and Recovery Act (RCRA). In the second quarter of 2014, DuPont filed a motion for summary judgment. The LHWA moved for partial summary judgment. During the second quarter, the court granted in part and denied in part both parties' motions for summary judgment, and a trial date is set for October. Chemours, through DuPont, denies these claims and is defending itself vigorously. PFOA Summary While it is probable that the company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing. To date, through June 30, 2015, less than $1 has been disbursed from the escrow account related to medical monitoring. Chemours believes that it is reasonably possible that it could incur losses related to other PFOA matters discussed above; however, a range of such losses cannot be reasonably estimated at this time due to the uniqueness of the individual MDL plaintiff's claims and Chemours' defenses to those claims, both as to potential liability and damages on an individual claim basis, among other factors. (c) Environmental DuPont, of which Chemours, prior to the distribution, was a subsidiary, is also subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Chemours accrues for environmental remediation activities consistent with the policy set forth in Note 3 to the Annual Combined Financial Statements in our Information Statement included in our Registration Statement. Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require DuPont, of which Chemours, prior to the distribution, was a subsidiary, to undertake certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other potentially responsible parties. At June 30, 2015, the Interim Consolidated Balance Sheets included a liability of $302, relating to these matters which, in management’s opinion, is appropriate based on existing facts and circumstances. The average time frame, over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15 to 20 years. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $650 above the amount accrued at June 30, 2015. Except for Pompton Lakes, which is discussed further below, based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the financial position, liquidity or results of operations of Chemours. Pompton Lakes The environmental remediation accrual at June 30, 2015 includes $86 related to activities at Chemours’ site in Pompton Lakes, New Jersey. Management believes that it is reasonably possible that potential liability for remediation activities at this site could range up to $116 including previously accrued amounts. This could have a material impact on the liquidity of Chemours in the period recognized. During the twentieth century, DuPont manufactured blasting caps, fuses and related materials at Pompton Lakes. Operating activities at the site were ceased in the mid 1990s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds. Under the authority of the EPA and the New Jersey Department of Environmental Protection, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is ongoing and Chemours, through DuPont, has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours, through DuPont, is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site's RCRA permit that requires Chemours to dredge mercury contamination from a 36 acre area of the lake and remove sediment from two other areas of the lake near the shoreline. Chemours expects to spend about $50 over the next two to three years in connection with remediation activities at Pompton Lakes, including activities related to the EPA’s proposed plan. These amounts are included in the remediation accrual at June 30, 2015.

Financial Instruments

6 Months Ended

Jun. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, Chemours enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency risks. The Company has established a new derivative program to be utilized for financial risk management. This program reflects varying levels of exposure coverage and time horizons based on an assessment of risk.

The derivative program has procedures consistent with Chemours’ financial risk management policies and guidelines. Derivative instruments used are forward currency exchange contracts. Chemours has not designated any derivatives as hedging instruments.

Commencing in February 2015, Chemours entered into stand-alone derivative contracts to minimize volatility in earnings resulting from translating net monetary assets that Chemours holds which are denominated in a non-functional currency. These derivative instruments are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. Chemours’ derivative assets and liabilities are reported on a gross basis in the Interim Consolidated Balance Sheets. No collateral has been required for these contracts.

At June 30, 2015, there were 78 forward exchange currency contracts outstanding with an aggregate notional value of $1,996.

Foreign Currency Contracts

Chemours uses forward exchange currency derivatives to reduce its net exposure, by currency, related to non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting. However, the required revaluation of the forward contracts and the associated non-functional currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. Although all of the derivative contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis in the Interim Consolidated Balance Sheets.

Fair Value of Derivative Instruments

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Interim Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	June 30, 2015		December 31, 2014
Asset derivatives:
Non-functional currency contracts	Accounts and notes receivable - trade, net	$	13	$	—
Total asset derivatives		$	13	$	—

Liability derivatives
Non-functional currency contracts	Other accrued liabilities	$	1	$	—
Total liability derivatives		$	1	$	—

We classify our foreign currency derivative contracts within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance/quality checks.

Effect of Derivative Instruments



	Amount of Gain Recognized in Statements of Operations
	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Non-functional currency contracts ¹	$	23	$	—	$	12	$	—

¹Gains on these contracts are included in other income, net for the three and six months ended June 30, 2015.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Long-Term Employee Benefits

6 Months Ended

Jun. 30, 2015

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Long-Term Employee Benefits

DuPont offers various long-term benefits to its employees. Where permitted by applicable law, DuPont reserves the right to change, modify or discontinue the Plans.

DuPont offers plans that are shared among its businesses, including Chemours. In these cases, the participation of employees in these plans is reflected in these financial statements as though Chemours participates in a multi-employer plan with DuPont. A proportionate share of the cost is reflected in these Interim Consolidated Financial Statements. Assets and liabilities of such plans are retained by DuPont. Further information on the DuPont plans is discussed in DuPont’s Annual Report on Form 10-K for the year ended December 31, 2014 (DuPont’s Annual Report).

On July 1, 2015, in connection with the separation from DuPont, Chemours employees will cease participating in the DuPont plans described below. Comparable defined contribution plans will be established in the U.S. and outside the U.S., certain non-U.S. pension plans, comparable to the DuPont plans, will be established after separation. In the U.S., enhanced 401(k) benefits will be provided to former participants of the pension plan.

(a) Defined Benefit Pensions

DuPont Pension and Retirement Plan

DuPont has both funded and unfunded noncontributory defined benefit pension plans covering a majority of the U.S. employees hired before January 1, 2007. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. DuPont’s funding policy is consistent with the funding requirements of federal laws and regulations.

Chemours will not continue to participate in the U.S. defined benefit plans after June 30, 2015. DuPont will retain all liabilities related to its U.S. pension plans post-separation. Certain Chemours employees were employed by DuPont prior to the separation, and were participants in DuPont's U.S. pension plan with vested plan balances at the separation date. These Chemours employees will receive pension payments from DuPont at the time of their retirement.

Non-U.S. Pension Plans

Pension coverage for employees of DuPont’s non-U.S. subsidiaries is provided, to the extent deemed appropriate, through separate plans. Obligations under such plans are funded by depositing funds with trustees, covered by insurance contracts or remain unfunded.

(b) Other Long-Term Employee Benefits

DuPont provides medical, dental and life insurance benefits to pensioners and survivors, and disability and life insurance protection to employees. The associated plans for retiree benefits are unfunded and the cost of approved claims are paid from DuPont funds. Essentially all of the cost for these retiree benefit plans is attributable to DuPont’s U.S. plans. The retiree medical plan is contributory with pensioners' and survivors’ contributions adjusted annually to achieve a 50/50 target sharing of cost increases between DuPont and pensioners and survivors. In addition, limits are applied to DuPont’s portion of the retiree medical cost coverage. U.S. employees hired on or after January 1, 2007 are not eligible to participate in the post-retirement medical, dental and life insurance plans. DuPont also provides disability benefits to employees. Employee disability benefit plans are insured in many countries. However, in the U.S., such plans are generally self-insured. Expenses for self-insured plans are reflected in the Consolidated Financial Statements.

DuPont sponsors several defined contribution plans, which cover substantially all U.S. employees. The most significant is DuPont’s U.S. Retirement Savings Plan, which reflects the 2009 merger of DuPont’s Retirement Savings Plan and DuPont’s Savings and Investment Plan. This plan includes a non-leveraged Employee Stock Ownership Plan (ESOP). Employees are not required to participate in the ESOP and those who do are free to diversify out of the ESOP. The purpose of the plan is to provide retirement savings benefits for employees and to provide employees an opportunity to become stockholders of DuPont. The plan is a tax-qualified contributory profit sharing plan, with cash or deferred arrangement, and any eligible employee of DuPont may participate. DuPont contributes 100% of the first 6% of the employee’s contribution election and also contributes 3% of each eligible employee’s eligible compensation regardless of the employee’s contribution.

Participation in the Plans

Chemours participates in DuPont’s U.S. and non-U.S. plans as though they are participants in a multi-employer plan with the other businesses of DuPont. More information on the financial status of DuPont’s significant plans can be found in DuPont’s Annual Report. The following table presents expense for DuPont’s significant plans in which Chemours participates and are accounted for as multi-employer plans.



		Three Months Ended June 30,				Six Months Ended June 30,
Plan Name	EIN / Pension Number	2015		2014		2015		2014
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	24	$	12	$	48	$	25
All other U.S. and non-U.S. Plans		2		—		5		3

The above table does not include pension plans covering Chemours' employees in the Netherlands and Taiwan plans. See section (d) below for further discussion of these plans. For purposes of these financial statements, the amounts in the tables above represent the allocation of cost to Chemours included in the income statements of Chemours, which was allocated based on active employee headcount. These figures do not represent cash payments to DuPont, or DuPont’s plans.

(d) Single and Multiple Employer Plans

Commencing in the first quarter of 2015, Chemours has accounted for the Plans covering its employees in the Netherlands and Taiwan as a multiple employer plan and a single employer plan, respectively. The pre-tax amounts recognized in accumulated other comprehensive (loss) income are summarized below:



Pension Benefits	June 30, 2015
Net loss	$	283
Prior service cost	9
Total amount recognized in accumulated other comprehensive (loss) income	$	292

At January 1, 2015, the accumulated benefit obligation, projected benefit obligation and fair value of assets in the Netherlands plan were $1,026, $1,092 and $1,184, respectively. At January 1, 2015, the accumulated benefit obligation, projected benefit obligation and fair value of assets in the Taiwan plan were $37, $54 and $0, respectively. DuPont, on behalf of Chemours, contributed $28 to the Taiwan plan in 2015. Valuations for the single and multiple employer plans covering Chemours' employees in the Netherlands and Taiwan were obtained as of January 1, 2015 and the information presented is in accordance with the valuation of these plans as of that date.



Pension Benefits	Three Months Ended June 30, 2015			Six Months Ended June 30, 2015
Components of net periodic pension cost:
Net periodic benefit (credit) cost:
Service cost	$	3		$	6
Interest cost	4			9
Expected return on plan assets	(20		)	(41		)
Amortization of loss	3			7
Amortization of prior service cost	1			2
Net periodic benefit (credit) cost	$	(9	)	$	(17	)

The estimated pre-tax net loss and prior service cost for the defined benefit pension plans that will be amortized from accumulated other comprehensive (loss) income into net periodic benefit cost during the remainder of 2015 is $9.

Assumptions

For the Netherlands and Taiwan plans, the Company utilizes prevailing long-term high quality corporate bond indices to determine the discount rate applicable to each country at the measurement date. For these plans, the long term rate of return on assets reflects economic assumptions applicable to each country.

The following assumptions have been used to determine the benefit obligations and net benefit cost:



Weighted average assumptions used to determine benefit obligations as of January 1, 2015 and benefit cost for the six months ended June 30, 2015	Pension Benefits
Discount rate	2	%
Expected return on plan assets	7	%
Rate of compensation increase ¹	4	%

¹ The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant's entire career at Chemours.

Plan Assets

The Netherlands and Taiwan plan assets are maintained by Chemours. Each pension plan's assets are invested through a master trust fund. The strategic asset allocation for this trust fund is selected by management, reflecting the results of comprehensive asset and liability modeling. Chemours establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. Strategic asset allocations in countries are selected in accordance with the laws and practices of those countries.

The weighted average target allocation for Chemours' Netherlands and Taiwan pension plan assets is summarized as follows:



	January 1, 2015
U.S. equity securities	22	%
Non-U.S.equity securities	20	%
Fixed income securities	58	%
Total	100	%

Fixed income securities include corporate issued, government issued and asset backed securities. Corporate debt investments include a range of credit risk and industry diversification. U.S. fixed income investments are weighted more heavily than non-U.S. fixed income securities.

Fair value calculations may not be indicative of net realizable value or reflective of future fair values. Furthermore, although Chemours believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The table below presents the fair values of Chemours' Netherlands and Taiwan pension assets by level within the fair value hierarchy, as described in Note 3 of the Interim Consolidated Financial Statements, as of January 1, 2015.




	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	523		$	—	$	523
Debt - corporate issued	136			43		93
Debt - asset backed	35			—		35
U.S. and non U.S. equities	486			—		486
Derivatives - asset position	33			—		33
Derivatives - liability position	(12		)	—		(12		)
	1,201			$	43	$	1,158
Pension trust payables ¹	(17		)
Total	$	1,184

¹Primarily payables for investment securities purchased.

For pension plan assets classified as Level 1, total fair value is either the price of the most recent trade at the time of the market close or the official close price, as defined by the exchange on which the asset is most actively traded on the last trading day of the period, multiplied by the number of units held without consideration of transaction costs.

For pension or other postretirement benefit plan assets classified as Level 2, where the security is frequently traded in less active markets, fair value is based on the closing price at the end of the period; where the security is less frequently traded, fair value is based on the price a dealer would pay for the security or similar securities, adjusted for any terms specific to that asset or liability. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance and quality checks. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates, commodity prices, swap rates, interest rates and implied volatilities obtained from various market sources.

Cash Flow

Defined Benefit Plan

No contributions were made to the principal U.S. pension plan trust fund in 2014. In 2015, DuPont's contributions on behalf of Chemours to its principal U.S. pension plan are expected to be less than $15.

DuPont contributed, on behalf of Chemours, $35 to its pension plans other than the principal U.S. pension plan in 2014. DuPont contributed, on behalf of Chemours, $66 to its other long-term employee benefit plans in 2014. DuPont contributed $38 in the first half of 2015 and Chemours expects to contribute an additional $5 to its pension plans other than the principal U.S. pension plan in the remainder of 2015, and expects contributions to its other long-term employee benefit plans to be approximately the same as contributions in 2014.

Estimated future benefit payments

The following benefit payments, which are related to non-U.S. plans that are predominantly Chemours and reflect future service, as appropriate, are expected to be paid:



Year ended December 31,	Benefits
Remainder of 2015	$	19
2016	39
2017	40
2018	41
2019	42
2020-2024	218

Defined Contribution Plan

DuPont's contributions to the plan on behalf of Chemours were allocated in the amounts of $52 for the year ended December 31, 2014. The plan's matching contributions vest immediately upon contribution. The three percent non-matching contribution vest for employees with at least three years of service. The contribution made by DuPont on behalf of Chemours is an allocation of the total contribution based on the headcount of the participants in the plan which are part of the Chemours business.

Segment Information

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Segment Information

Chemours’ operations are classified into three reportable segments based on similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution and regulatory environment. Chemours’ reportable segments are Titanium Technologies, Fluoroproducts and Chemical Solutions. Corporate costs and certain legal and environmental expenses that are not aligned with the reportable segments are reflected in Corporate and Other.

Segment sales include transfers to another reportable segment. Adjusted EBITDA is the primary measure of segment profitability used by the Chief Operating Decision Maker (CODM) and is defined as income (loss) before income taxes, depreciation and amortization excluding non-operating pension and other postretirement employee benefit costs, exchange gains (losses), restructuring charges (benefits) and gains (losses) on sale of business or assets. Prior to June 30, 2015, the Company did not include restructuring charges (benefits) and gains (losses) on sale of business or assets in adjusted EBITDA. The tables presented below reflect the current definition of adjusted EBITDA for all periods presented. Corporate costs and certain legal and environmental expenses that are not aligned with the reportable segments are reflected in Corporate and Other. Adjusted EBITDA includes service cost component of net periodic benefit cost. All other components of net periodic benefit cost are considered non-operating and are excluded for adjusted EBITDA.



Three Months Ended June 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Sales	$	642	$	588	$	278	$	—		$	1,508
Less: Transfers	—		—		—		—			—
Net sales	$	642	$	588	$	278	$	—		$	1,508
Adjusted EBITDA	95		66		7		(41		)	$	127
Depreciation and amortization	32		21		14		—			67

2014
Sales	$	788	$	601	$	295	$	—		$	1,684
Less: Transfers	2		—		—		—			2
Net sales	$	786	$	601	$	295	$	—		$	1,682
Adjusted EBITDA	210		77		8		(60		)	235
Depreciation and amortization	31		21		12		—			64



Six Months Ended June 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Sales	$	1,188	$	1,140	$	544	$	—		$	2,872
Less: Transfers	1		—		—		—			1
Net sales	$	1,187	$	1,140	$	544	$	—		$	2,871
Adjusted EBITDA	194		147		10		(79		)	272
Depreciation and amortization	63		42		26		—			131

2014
Sales	$	1,499	$	1,180	$	576	$	—		$	3,255
Less: Transfers	4		—		—		—			4
Net sales	$	1,495	$	1,180	$	576	$	—		$	3,251
Adjusted EBITDA	390		151		15		(120		)	436
Depreciation and amortization	61		43		24		—			128

Total segment EBITDA reconciles to total consolidated income before income taxes on the Interim Consolidated Statements of Operations as follows:

Reconciliation to Consolidated Statements of Operations



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Total segment adjusted EBITDA	$	127		$	235		$	272		$	436
Interest	(28		)	—			(28		)	—
Depreciation and amortization	(67		)	(64		)	(131		)	(128		)
Non-operating pension and other postretirement employee benefit costs	(8		)	(10		)	(15		)	(15		)
Exchange gains (losses)	19			5			3			4
Restructuring charges	(61		)	(20		)	(61		)	(21		)
Gains (losses) on sale of business or assets	—			9			—			11
(Loss) income before income taxes	$	(18	)	$	155		$	40		$	287

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In connection with the preparation of the consolidated financial statements and in accordance with GAAP, the Company evaluated subsequent events after the balance sheet date of June 30, 2015 through the date these financial statements were issued. Equity Compensation In accordance with the Employee Matters Agreement between DuPont and Chemours, certain executives and employees were entitled to receive equity compensation awards of Chemours in replacement of previously outstanding awards granted under various DuPont stock incentive plans prior to the separation. The compensation expense for these awards, which were issued by DuPont, was reflected in our statement of operations for all historical periods. In connection with the spin-off, these awards were converted into new Chemours equity awards using a formula designed to preserve the intrinsic value of the awards immediately prior to the July 1, 2015 spin-off. As a result of the conversion of these awards, and new Chemours equity awards granted subsequent to the spin-off, we will record an approximate $6 charge in the third quarter and an approximate $18 charge over the remaining life of the instruments.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Foreign Currency Translation	Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: 1) extension of the parent (U.S. dollar functional currency) and 2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed. During the periods covered by the Interim Consolidated Financial Statements, part of the Chemours business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, except for inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, which are remeasured at historical rates. Foreign currency-denominated income and expenses are remeasured at average exchange rates in effect during the period, except for expenses related to balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollar at end-of-period exchange rates and the resulting translation adjustments are reported as a component of accumulated other comprehensive (loss) income in equity. Assets and liabilities denominated in other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars and the resulting exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into U.S. dollars at average exchange rates in effect during the period. Beginning in 2015, when the Performance Chemicals operations were legally and operationally separated within DuPont in anticipation of the spin-off, some of the resulting newly created Chemours foreign entities set their local currency as the functional currency.
Employee Benefits	Employee Benefits Certain of Chemours’ employees participate in defined benefit pension and other post-employment benefit plans (the Plans) sponsored by DuPont and accounted for by DuPont in accordance with accounting guidance for defined benefit pension and other post-employment benefit plans. Substantially all expenses related to these plans were allocated in shared entities and reported within costs of goods sold, selling, general and administrative expenses and research and development expense in the Interim Consolidated Statements of Operations. Chemours considered all plans to be part of a multi-employer plan with DuPont prior to January 1, 2015. In connection with the spin-off, Chemours retained the existing Netherlands pension plan and an agreement was executed in 2015 to ensure continuance of the plan for both DuPont and Chemours employees and retirees. As a result of that agreement, Chemours now accounts for the Netherlands plan as a multiple employer plan. Additionally, in 2015, Chemours formed a new pension plan in Taiwan that mirrors the plan historically operated by DuPont in Taiwan. The new Taiwan plan is accounted for under the single employer method. For both of these plans, the assets, liabilities and expenses applicable to Chemours are included in these Interim Consolidated Financial Statements (See Note 17 for further information).
Derivatives	Derivatives Prior to 2015, Chemours participated in DuPont’s foreign currency hedging program to reduce earnings and cash flow volatility associated with foreign currency exchange rate changes. DuPont formally documented the hedge relationships, including identification of the hedging instruments and the hedged items, the risk management objectives and strategies for undertaking the hedge transactions and the methodologies used to assess effectiveness and measure ineffectiveness. Realized gains and losses on derivative instruments of DuPont were allocated by DuPont to Chemours based on projected exposure. Chemours recognized its allocable share of the gains and losses on DuPont’s derivative financial instruments in earnings when the forecasted sales occurred for foreign currency hedges. The foreign currency hedges qualified as cash flow hedges, and the realized gains recognized in earnings were less than $1 for the three and six months ended June 30, 2014. Chemours’ participation in this program terminated as of January 1, 2015. Beginning in February 2015, Chemours began entering into forward currency exchange contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring net monetary assets that Chemours holds which are denominated in non-functional currencies. These derivatives are stand-alone and are not part of a cash flow hedge or fair value hedge program, and have not been designated as a hedge. The derivative assets and liabilities are reported on a gross basis in the Interim Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Interim Consolidated Statements of Operations during the period in which they occurred. Chemours does not hold or issue financial instruments for speculative or trading purposes.
Fair Value Measurement	Fair Value Measurement Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical asset and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours uses the following valuation techniques to measure fair value for its assets and liabilities: (a) Level 1—Quoted market prices in active markets for identical assets and liabilities (b) Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and (c) Level 3—Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-07, "Fair Value Measurement (Topic 820) - Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share or its Equivalent." This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The guidance is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours is currently evaluating the impact of adopting this guidance. In April 2015, the FASB issued ASU No. 2015-03, “Interest — Imputation of Interest (Subtopic 835-30),” which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of the debt, consistent with debt discounts. The ASU is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. Chemours adopted this guidance for the quarter ending June 30, 2015. The adoption of this standard has no impact on Chemours’ results of operations or cash flows. Due to the accounting change described above, Chemours recorded debt issuance costs incurred for the issuance of its senior secured term loans and senior unsecured notes as a reduction of the liability on the Interim Consolidated Balance Sheets. See Note 14 for additional information. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments under the new guidance modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The ASU is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. A reporting entity also may apply the amendments retrospectively. Chemours is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In May 2014, the FASB and the International Accounting Standards Board (IASB) jointly issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards (IFRS). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The ASU is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date). In July 2015, the FASB approved a deferral of the effective date of the ASU to provide entities with adequate time to effectively implement the new revenue standard and adoption as of the original effective date is permitted. The Company is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” amending existing requirements for reporting discontinued operations. Under the new guidance, discontinued operations reporting will be limited to disposal transactions that represent strategic shifts having a major effect on operations and financial results. The amended guidance also enhances disclosures and requires assets and liabilities of a discontinued operation to be classified as such for all periods presented in the financial statements. Public entities will apply the amended guidance prospectively to all disposals occurring within annual periods beginning on or after December 15, 2014 and interim periods within those years. Chemours adopted this standard on January 1, 2015. Due to the change in requirements for reporting discontinued operations described above, presentation and disclosures of future disposal transactions after adoption may be different than under current standards.

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References + Details

- Definition

Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.

+ References + Details

Basis of Presentation (Tables)

6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Earnings Per Share, Pro Forma



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015		2014
Net (loss) income attributable to Chemours (as reported)	$	(18	)	$	116		$	25	$	214
Historical pro forma earnings per share data
(Loss) earnings per share attributable to Chemours
Basic and diluted	(0.10		)	0.64		¹	0.14		1.18		¹
Weighted average number of shares outstanding
Basic and diluted	180,996,833			180,996,833			180,996,833		180,996,833

Relationship with DuPont and Related Entities (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of Related Party Transactions

Related party sales to other DuPont businesses include the following amounts:



Selling Segment	Three Months Ended June 30,				Six Months Ended June 30,
Selling Segment	2015		2014		2015		2014
Titanium Technologies	$	1	$	—	$	2	$	—
Fluoroproducts	16		12		34		24
Chemical Solutions	11		22		21		41
Total	$	28	$	34	$	57	$	65

Employee Separation and Asset Related Charges, Net (Tables)

6 Months Ended

Jun. 30, 2015

Restructuring Charges [Abstract]

Schedule of Restructuring Program

The charges related to the 2015 and 2014 restructuring programs impacted segment earnings as follows:



	Three and Six Months Ended June 30,
	2015			2014
2015 Restructuring Plan
Titanium Technologies	$	23		$	—
Fluoroproducts	25			—
Chemical Solutions	13			—
Total	$	61	¹	$	—

2014 Restructuring Plan
Titanium Technologies	$	—		$	3
Fluoroproducts	—			16
Total	$	—		$	19

¹ Includes approximately $13 related to Corporate overhead functions that was allocated to our segments.

The following table shows the change in the liability account balance associated with our restructuring plans and activity related to the 2015 and 2014 restructuring programs.



	Employee Separation Costs
	2015 Restructuring Plan			2014 Restructuring Plan
Balance as of December 31, 2014	$	—		$	12
Charges to income for the six months ended June 30, 2015	61			—
Charges to liability accounts:
Payments ¹	(8		)	(9		)
Net currency translation adjustment	—			—
Balance as of June 30, 2015	$	53		$	3

¹Payments related to the 2015 restructuring plan were made in the second quarter of 2015. For the 2014 plan, payments of $2 and $7 were made in the first and second quarters of 2015, respectively.

Other Income, Net (Tables)

6 Months Ended

Jun. 30, 2015

Other Income and Expenses [Abstract]

Schedule of Other Income



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Leasing, contract services and miscellaneous income ¹	$	—	$	2	$	4	$	5
Royalty income²	2		4		7		9
Gain on sale of assets and businesses ³	—		9		—		11
Exchange gains (losses), net ⁴	19		5		3		4
Total other income, net	$	21	$	20	$	14	$	29

¹Leasing, contract services and miscellaneous income includes accrued interest related to unrecognized tax benefits.

² Royalty income is primarily for technology and trademark licensing.

³Gain on sale of assets and businesses primarily relates to a sale of assets in the Fluoroproducts segment.

Accounts and Notes Receivable - Trade, Net (Tables)

6 Months Ended

Jun. 30, 2015

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable



	June 30, 2015		December 31, 2014
Accounts receivable—trade, net ¹	$	896	$	746
VAT, GST and other taxes ²	86		62
Advances and deposits	14		15
Leases receivable—current	12		12
Notes receivable—trade ³	30		11
Total	$	1,038	$	846

¹Accounts receivable – trade is net of allowances of $4 and $4 as of June 30, 2015 and December 31, 2014, respectively. Allowances are equal to the estimated uncollectible amounts.

²Value Added Tax (VAT) and Goods and Services Tax (GST) receivables are generally recorded at the legal entity level and allocated to Chemours within shared legal entities.

Inventories (Tables)

6 Months Ended

Jun. 30, 2015

Inventory, Net [Abstract]

Schedule of Inventories



	June 30, 2015			December 31, 2014
Finished products	$	703		$	611
Semi-finished products	160			173
Raw materials, stores and supplies	437			521
Subtotal	1,300			1,305
Adjustment of inventories to a last-in, first-out (LIFO) basis	(246		)	(253		)
Total	$	1,054		$	1,052

Intangible Assets, Net (Tables)

6 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Other Intangible Assets

The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:



	June 30, 2015							December 31, 2014
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer lists	$	19	$	(17	)	$	2	$	19	$	(16	)	$	3
Patents	20		(17		)	3		20		(16		)	4
Purchased trademarks	18		(14		)	4		18		(14		)	4
Purchased and licensed technology	20		(17		)	3		17		(17		)	—
Total	$	77	$	(65	)	$	12	$	74	$	(63	)	$	11

Other Assets (Tables)

6 Months Ended

Jun. 30, 2015

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Assets



	June 30, 2015		December 31, 2014
Leases receivable - non-current¹	$	131	$	137
Capitalized repair and maintenance costs	149		185
Pension assets ²	115		—
Advances and deposits	14		17
Deferred income taxes - non-current	23		9
Miscellaneous ³	39		27
Total	$	471	$	375

¹Leases receivable includes direct financing type leases of property at two locations. See Note 9 for further information.

²Pension assets represent pension plans commencing in 2015 covering Chemours' employees in the Netherlands and Taiwan. See Note 17 for further information.

Debt (Tables)

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments



	June 30, 2015
Long-term debt:
Senior secured term loan, net of issue discount	$	1,493
Senior unsecured notes:
6.625%, due May 2023	1,350
7.00%, due May 2025	750
6.125%, due May 2023 (€360)	403
Other	3
Total	3,999
Less: Unamortized debt issuance costs	56
Less: Current maturities	16
Total long-term debt	$	3,927

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Assets at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Interim Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	June 30, 2015		December 31, 2014
Asset derivatives:
Non-functional currency contracts	Accounts and notes receivable - trade, net	$	13	$	—
Total asset derivatives		$	13	$	—

Liability derivatives
Non-functional currency contracts	Other accrued liabilities	$	1	$	—
Total liability derivatives		$	1	$	—

Schedule of Derivative Liabilities at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Interim Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	June 30, 2015		December 31, 2014
Asset derivatives:
Non-functional currency contracts	Accounts and notes receivable - trade, net	$	13	$	—
Total asset derivatives		$	13	$	—

Liability derivatives
Non-functional currency contracts	Other accrued liabilities	$	1	$	—
Total liability derivatives		$	1	$	—

Derivative Instruments, Gain (Loss)



	Amount of Gain Recognized in Statements of Operations
	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Non-functional currency contracts ¹	$	23	$	—	$	12	$	—

¹Gains on these contracts are included in other income, net for the three and six months ended June 30, 2015.

Long-Term Employee Benefits (Tables)

6 Months Ended

Jun. 30, 2015

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Schedule of Multiemployer Plans

The following table presents expense for DuPont’s significant plans in which Chemours participates and are accounted for as multi-employer plans.



		Three Months Ended June 30,				Six Months Ended June 30,
Plan Name	EIN / Pension Number	2015		2014		2015		2014
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	24	$	12	$	48	$	25
All other U.S. and non-U.S. Plans		2		—		5		3

Schedules of Net Periodic Benefit Cost



Pension Benefits	Three Months Ended June 30, 2015			Six Months Ended June 30, 2015
Components of net periodic pension cost:
Net periodic benefit (credit) cost:
Service cost	$	3		$	6
Interest cost	4			9
Expected return on plan assets	(20		)	(41		)
Amortization of loss	3			7
Amortization of prior service cost	1			2
Net periodic benefit (credit) cost	$	(9	)	$	(17	)

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

The pre-tax amounts recognized in accumulated other comprehensive (loss) income are summarized below:



Pension Benefits	June 30, 2015
Net loss	$	283
Prior service cost	9
Total amount recognized in accumulated other comprehensive (loss) income	$	292

Schedule of Assumptions Used

The following assumptions have been used to determine the benefit obligations and net benefit cost:



Weighted average assumptions used to determine benefit obligations as of January 1, 2015 and benefit cost for the six months ended June 30, 2015	Pension Benefits
Discount rate	2	%
Expected return on plan assets	7	%
Rate of compensation increase ¹	4	%

¹ The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant's entire career at Chemours.

Schedule of Allocation of Plan Assets




	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	523		$	—	$	523
Debt - corporate issued	136			43		93
Debt - asset backed	35			—		35
U.S. and non U.S. equities	486			—		486
Derivatives - asset position	33			—		33
Derivatives - liability position	(12		)	—		(12		)
	1,201			$	43	$	1,158
Pension trust payables ¹	(17		)
Total	$	1,184

¹Primarily payables for investment securities purchased.

The weighted average target allocation for Chemours' Netherlands and Taiwan pension plan assets is summarized as follows:



	January 1, 2015
U.S. equity securities	22	%
Non-U.S.equity securities	20	%
Fixed income securities	58	%
Total	100	%

Schedule of Expected Benefit Payments

The following benefit payments, which are related to non-U.S. plans that are predominantly Chemours and reflect future service, as appropriate, are expected to be paid:



Year ended December 31,	Benefits
Remainder of 2015	$	19
2016	39
2017	40
2018	41
2019	42
2020-2024	218

Segment Information (Tables)

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Schedule of Segment Information



Three Months Ended June 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Sales	$	642	$	588	$	278	$	—		$	1,508
Less: Transfers	—		—		—		—			—
Net sales	$	642	$	588	$	278	$	—		$	1,508
Adjusted EBITDA	95		66		7		(41		)	$	127
Depreciation and amortization	32		21		14		—			67

2014
Sales	$	788	$	601	$	295	$	—		$	1,684
Less: Transfers	2		—		—		—			2
Net sales	$	786	$	601	$	295	$	—		$	1,682
Adjusted EBITDA	210		77		8		(60		)	235
Depreciation and amortization	31		21		12		—			64



Six Months Ended June 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Sales	$	1,188	$	1,140	$	544	$	—		$	2,872
Less: Transfers	1		—		—		—			1
Net sales	$	1,187	$	1,140	$	544	$	—		$	2,871
Adjusted EBITDA	194		147		10		(79		)	272
Depreciation and amortization	63		42		26		—			131

2014
Sales	$	1,499	$	1,180	$	576	$	—		$	3,255
Less: Transfers	4		—		—		—			4
Net sales	$	1,495	$	1,180	$	576	$	—		$	3,251
Adjusted EBITDA	390		151		15		(120		)	436
Depreciation and amortization	61		43		24		—			128

Reconciliation of EBITDA from Segments to Consolidated

Reconciliation to Consolidated Statements of Operations



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Total segment adjusted EBITDA	$	127		$	235		$	272		$	436
Interest	(28		)	—			(28		)	—
Depreciation and amortization	(67		)	(64		)	(131		)	(128		)
Non-operating pension and other postretirement employee benefit costs	(8		)	(10		)	(15		)	(15		)
Exchange gains (losses)	19			5			3			4
Restructuring charges	(61		)	(20		)	(61		)	(21		)
Gains (losses) on sale of business or assets	—			9			—			11
(Loss) income before income taxes	$	(18	)	$	155		$	40		$	287

Background and Description of the Business (Narrative) (Details)		6 Months Ended
	Jul. 01, 2015	Jun. 30, 2015 facility segment	Jun. 23, 2015 $ / shares
Segment Reporting Information [Line Items]
Number of reportable segments \| segment		3
Number of facilities		40
Common stock, par value \| $ / shares			$ 0.01
Parent Company [Member]
Segment Reporting Information [Line Items]
Number of facilities in which DuPont will continue control		3
Common stock, par value \| $ / shares			$ 0.30
Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of facilities		2
Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Number of facilities		6
Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Number of facilities		20
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities		12
Subsequent Event [Member]
Segment Reporting Information [Line Items]
New shares issued per share of parent	0.2

Basis of Presentation (Details) - USD ($) $ in Millions			6 Months Ended
Basis of Presentation (Details) - USD ($) $ in Millions	Jul. 01, 2015	Jun. 09, 2015	Jun. 30, 2015
Subsequent Event [Line Items]
Noncash contribution			$ 93
Dividends declared		$ 100	$ 100
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock issued, common stock	180,996,833

Basis of Presentation (Pro Forma Earnings Per Share) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	May 12, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income	$ (18)	$ 116	$ 25	$ 214
(Loss) earnings per share, basic	$ (0.10)	$ 0.64	$ 0.14	$ 1.18
(Loss) earnings per share, diluted	$ (0.10)	$ 0.64	$ 0.14	$ 1.18
Weighted average number of shares outstanding, basic	180,996,833	180,996,833	180,996,833	180,996,833
Weighted average number of shares outstanding, diluted	180,996,833	180,996,833	180,996,833	180,996,833
Long-term debt					$ 4,003

Summary of Significant Accounting Policies Summary of SIgnificant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
Accounting Policies [Abstract]
Realized gains recognized in earnings, less than	$ 1	$ 1

Research and Development Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	$ 27	$ 40	$ 50	$ 77
Projects Incurred by Chemours [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	21	27	40	50
Corporate Central Research and Development [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	$ 6	$ 13	$ 10	$ 27

Relationship with DuPont and Related Entities (Related Party Purchases and Sales) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Related Party Transaction [Line Items]
Related party sales	$ 0	$ 2	$ 1	$ 4
Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales	28	34	57	65
Titanium Technologies [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales	1	0	2	0
Fluoroproducts [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales	16	12	34	24
Purchases from related party	1		2
Chemical Solutions [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales	$ 11	22	$ 21	41
Purchases from related party		$ 1		$ 1

Relationship with DuPont and Related Entities (Leveraged Services and Corporate Costs) (Details) - Affiliated Entity [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 116	$ 131	$ 238	$ 257
Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	100	110	205	213
Research and Development Expense [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	6	13	10	27
Cost of Goods [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 10	$ 8	$ 23	$ 17

Relationship with DuPont and Related Entities (Details)	Jun. 30, 2015 USD ($) facility	Dec. 31, 2014 USD ($)
Related Party Transaction [Line Items]
Number of facilities	40
Cash \| $	$ 247,000,000	$ 0
Spin Off Transaction, Cash Target \| $	$ 200,000,000
DuPont [Member]
Related Party Transaction [Line Items]
Number of facilities	14
Manufacturing Operations [Member]
Related Party Transaction [Line Items]
Number of facilities	40

Employee Separation and Asset Related Charges, Net Employee Separation and Asset Related Charges, Net (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 61	$ 0	$ 61	$ 0
Expected cost remaining	$ 53	53		53
2015 Restructuring Program [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 61			61
2014 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 0	$ 19	0	$ 19	$ 19
2014 Restructuring Program [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 0		16
2014 Restructuring Program [Member] \| Asset Shut Down Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges						$ 3

Employee Separation and Asset Related Charges, Net (Segment Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 61	$ 0	$ 61	$ 0
2014 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	19	0	19	$ 19
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	23	0	23	0
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	25	0	25	0
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	13	0	13	0
Operating Segments [Member] \| 2014 Restructuring Program [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	3	0	3
Operating Segments [Member] \| 2014 Restructuring Program [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 0	$ 16	0	$ 16
Corporate, Non-Segment [Member] \| 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 13

Employee Separation and Asset Related Charges, Net (Restructuring Program schedule) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
2015 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges		$ 61		$ 0	$ 61	$ 0
2014 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges		0		$ 19	0	$ 19	$ 19
Payments		(7)	$ (2)
Employee Severance [Member] \| 2015 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve			0		0
Restructuring charges	$ 61				61
Payments					(8)
Net currency translation adjustment					0
Restructuring reserve	53	53			53		0
Employee Severance [Member] \| 2014 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve			$ 12		12
Restructuring charges					0		16
Payments					(9)
Net currency translation adjustment					0
Restructuring reserve	$ 3	$ 3			$ 3		$ 12

Other Income, Net (Schedule of Other Income) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Component of Other Income [Line Items]
Exchange gains (losses), net	$ 19	$ 5	$ 3	$ 4
Total other income, net	21	20	14	29
Exchange gains (losses),net	(4)		(9)
Foreign Exchange Contract [Member]
Component of Other Income [Line Items]
Gain on derivative	23		12
Other Income [Member]
Component of Other Income [Line Items]
Leasing, contract services and miscellaneous income	0	2	4	5
Royalty income	2	4	7	9
Gain on sale of assets and businesses	0	9	0	11
Exchange gains (losses), net	19	5	3	4
Total other income, net	$ 21	$ 20	$ 14	$ 29

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes	$ 0	$ 39,000,000	$ 15,000,000	$ 73,000,000
High end of range estimate of reasonably possible change in income tax expense	160,000,000		160,000,000
DuPont company net investment	836,000,000		836,000,000		$ 3,650,000,000
Deferred Taxes Associated with Pension Plans [Member] \| Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred tax assets	(23,000,000)		(23,000,000)
Deferred tax liabilities	49,000,000		49,000,000
DuPont company net investment	$ (72,000,000)		$ (72,000,000)

Accounts and Notes Receivable - Trade, Net (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for Doubtful Accounts Receivable	$ 4,000,000		$ 4,000,000		$ 4,000,000
Bad debt expense	1,000,000	$ 1,000,000	1,000,000	$ 1,000,000
Capital Leases, Future Minimum Payments Receivable	143,000,000		143,000,000		$ 149,000,000
Capital Leases, Net Investment in Direct Financing Leases, Unguaranteed Residual Values of Leased Property	0		0
Notes Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Derivative assets	$ 13,000,000		$ 13,000,000

Accounts and Notes Receivable - Trade, Net (Schedule of Accounts and Notes Receivable) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable—trade, net	$ 896	$ 746
VAT, GST and other taxes	86	62
Advances and deposits	14	15
Leases receivable—current	12	12
Notes receivable—trade	30	11
Total	$ 1,038	$ 846

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Finished products	$ 703	$ 611
Semifinished products	160	173
Raw materials, stores and supplies	437	521
Total inventories before LIFO adjustment	1,300	1,305
Adjustment of inventories to a last-in, first-out (LIFO) basis	(246)	(253)
Total	1,054	1,052
LIFO inventory amount	$ 652	$ 684
Percentage of LIFO inventory	50.00%	52.00%

Property, Plant, and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 66	$ 64	$ 129	$ 127
Capital leased assets	$ 7		$ 7		$ 6

Intangible Assets, Net (Schedule of Other Intangible Assets) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	$ 77	$ 74
Definite-lived Intangible Assets, Accumulated Amortization	(65)	(63)
Definite-lived Intangible Assets, Net	12	11
Customer Lists [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	19	19
Definite-lived Intangible Assets, Accumulated Amortization	(17)	(16)
Definite-lived Intangible Assets, Net	2	3
Patents [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	20	20
Definite-lived Intangible Assets, Accumulated Amortization	(17)	(16)
Definite-lived Intangible Assets, Net	3	4
Trademarks [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	18	18
Definite-lived Intangible Assets, Accumulated Amortization	(14)	(14)
Definite-lived Intangible Assets, Net	4	4
Purchased and Licensed Technology [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	20	17
Definite-lived Intangible Assets, Accumulated Amortization	(17)	(17)
Definite-lived Intangible Assets, Net	$ 3	$ 0

Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Minimum [Member]
Goodwill and Other Intangible Assets
Useful life			5 years
Maximum [Member]
Goodwill and Other Intangible Assets
Useful life			20 years
Continuing Operations [Member]
Goodwill and Other Intangible Assets
Aggregate pre-tax amortization expense	$ 1	$ 1	$ 2	$ 1

Other Assets (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Leases receivable - non-current	$ 131	$ 137
Capitalized repair and maintenance costs	149	185
Pension assets	115	0
Advances and deposits	14	17
Deferred income taxes - non-current	23	9
Miscellaneous	39	27
Total	471	375
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Deferred financing fee	$ 20	$ 20

Debt (Components of Long-Term Debt) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt	$ 3,999
Less: Unamortized debt issuance costs	56
Less: Current maturities	16	$ 0
Total long-term debt	3,927	$ 0
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,350
Debt instrument interest rate	6.625%
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 750
Debt instrument interest rate	7.00%
Senior Notes [Member] \| 6.125% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 403
Debt instrument interest rate	6.125%
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Long-term debt	$ 3
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term debt	1,493
Unamortized discount	$ 7

Debt (Senior Secured Credit Facilities) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2015 USD ($)	May 12, 2015 USD ($)
The Term Loan Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term	7 years
Line of credit facility, maximum borrowing capacity		$ 1,500
Periodic payment, percentage of face amount	1.00%
Principal payment	$ 8
Line of credit facility, additional borrowing capacity allowed		700
Leverage ratio maximum	1.50
Unamortized discount	$ 7
Stated percentage rate, minimum	3.75%
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term	5 years
Line of credit facility, maximum borrowing capacity		$ 1,000
Leverage ratio maximum	3.00
Letters of credit outstanding	$ 126
Commitment fee percentage	0.30%
Minimum [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage	0.20%
Maximum [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage	0.35%
Base Rate [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Variable rate	1.00%
Base Rate [Member] \| Minimum [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Variable rate	0.50%
Base Rate [Member] \| Maximum [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Variable rate	1.25%
London Interbank Offered Rate (LIBOR) [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Variable rate	2.00%
London Interbank Offered Rate (LIBOR) [Member] \| Minimum [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Variable rate	1.50%
London Interbank Offered Rate (LIBOR) [Member] \| Maximum [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Variable rate	2.25%
Domestic Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock	100.00%
Foreign Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock	65.00%

Debt (Senior Unsecured Notes) (Details) € in Millions	6 Months Ended
Debt (Senior Unsecured Notes) (Details) € in Millions	Jun. 30, 2015 USD ($)	Jun. 30, 2015 EUR (€)	May 12, 2015 USD ($)	May 12, 2015 EUR (€)
Debt Instrument [Line Items]
Long-term debt, gross			$ 4,003,000,000
Long-term debt	$ 3,999,000,000
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross			2,503,000,000
Debt Instrument, interest rate, additional	0.25%	0.25%
Threshold consecutive days following registration default	90 days
Threshold consecutive days following registration default, additional	90 days
Debt Instrument, interest rate additional maximum	0.50%	0.50%
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross			1,350,000,000
Long-term debt	$ 1,350,000,000
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt, gross			750,000,000
Long-term debt	750,000,000
Debt Instrument, face amount			$ 507,000,000
Senior Notes [Member] \| 6.125% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross \| €		€ 360		€ 360
Long-term debt	$ 403,000,000

Debt (Maturities and Fair Value) (Details) $ in Millions	Jun. 30, 2015 USD ($)
The Term Loan Facility [Member]
Debt Instrument [Line Items]
2015	$ 8
2016	15
2017	15
2018	15
2019	15
2020	15
2021	15
2022 and beyond	3,905
Fair Value, Inputs, Level 2 [Member] \| Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	1,313
Fair Value, Inputs, Level 2 [Member] \| Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Notes, fair value	728
Fair Value, Inputs, Level 2 [Member] \| Senior Notes [Member] \| 6.125% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	387
Fair Value, Inputs, Level 2 [Member] \| The Term Loan Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 1,491

Commitments and Contingent Liabilities (Guarantees) (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Guarantee obligations	$ 2	$ 41

Commitments and Contingent Liabilities (Litigation) (Narrative) (Details) resident in Thousands, $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2015 USD ($) lawsuit	Jun. 30, 2015 USD ($) lawsuit	Dec. 31, 2005 USD ($)	Dec. 31, 2004 resident	Mar. 31, 2015 lawsuit	Dec. 31, 2014 USD ($)	Sep. 30, 2014	Jan. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Loss contingency, potential additional loss	$ 650	$ 650
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit	2,500	2,500
Accrual balance	$ 38	$ 38				$ 38
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance	$ 14	$ 14				$ 14
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size \| resident				80
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit	3,500	3,500			3,500
Lawsuits alleging personal injury, number of new claims filed \| lawsuit	50
Claims dismissed \| lawsuit	40
Lawsuits alleging wrongful death	37	37
PFOA MDL plaintiffs							6
Payment for Plaintiffs Attorney Fees [Member] \| PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Settlement payments			$ 23
Payment to fund community health project [Member] \| PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Settlement payments			$ 70
Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit disbursements		$ 1
Funding for medical monitoring program [Member] \| PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss	$ 235	$ 235
Escrow deposit								$ 1

Commitments and Contingent Liabilities (Environmental) (Narrative) (Details)	6 Months Ended
	Jun. 30, 2015 USD ($) a
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	$ 302,000,000
Loss Contingency, Range of Possible Loss, Maximum	$ 650,000,000
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	15 years
Maximum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	20 years
Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	$ 86,000,000
Loss Contingency, Range of Possible Loss, Maximum	$ 116,000,000
Area of Lake \| a	36
Environmental Remediation Expense	$ 50,000,000
Pompton Lakes [Member] \| Minimum [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	2 years
Pompton Lakes [Member] \| Maximum [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	3 years

Financial Instruments (Details) $ in Millions	Jun. 30, 2015 USD ($) contract
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	78
Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative notional value \| $	$ 1,996

Financial Instruments (Schedule of the Fair Value of Derivative Instruments) (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 13		$ 13		$ 0
Liability derivatives	1		1		0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Foreign Exchange Contract [Member] \| Trade Accounts Receivable [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	13		13		0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Foreign Exchange Contract [Member] \| Accrued Liabilities and Other Liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	1		1		$ 0
Other Income [Member] \| Foreign Exchange Contract [Member]
Derivatives, Fair Value [Line Items]
Derivative amount of loss recognized in statements of operations	$ 23	$ 0	$ 12	$ 0

Long Term Employee Benefits Defined Benefit Plans (Narrative) (Details) - Parent Company [Member]	6 Months Ended
	Jun. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%
Defined Contribution Plan, Employer Discretionary Contribution, Percent of Employees' Gross Pay	3.00%

Long-Term Employee Benefits (Mulitemployer Plan) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
DuPont Pension and Retirement Plan (U.S.) [Member]
Multiemployer Plans [Line Items]
Pension and Other Postretirement Benefit Expense	$ 24	$ 12	$ 48	$ 25
Other U.S. and non-U.S. Plans [Member]
Multiemployer Plans [Line Items]
Pension and Other Postretirement Benefit Expense	$ 2	$ 0	$ 5	$ 3

Long-Term Employee Benefits (Single and Multiple Employer Plans) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Jan. 01, 2015
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Net of Tax	$ 1	$ 0	$ 2	$ 0
Foreign Pension Plan [Member]
Pension Benefits
Defined Benefit Plan, Fair Value of Plan Assets						$ 1,201
Foreign Pension Plan [Member] \| Netherlands and Taiwan [Member]
Pension Benefits
Net loss	283		283
Prior service cost	9		9
Total amount recognized in accumulated other comprehensive (loss) income	$ 292		292
Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year			9
Foreign Pension Plan [Member] \| Netherlands [Member]
Pension Benefits
Defined Benefit Plan, Accumulated Benefit Obligation						1,026
Defined Benefit Plan, Benefit Obligation						1,092
Defined Benefit Plan, Fair Value of Plan Assets						1,184
Foreign Pension Plan [Member] \| Taiwan [Member]
Pension Benefits
Defined Benefit Plan, Accumulated Benefit Obligation						37
Defined Benefit Plan, Benefit Obligation						54
Defined Benefit Plan, Fair Value of Plan Assets						$ 0
Parent Company [Member] \| Foreign Pension Plan [Member]
Pension Benefits
Defined Benefit Plan, Contributions by Employer			38		$ 35
Parent Company [Member] \| Foreign Pension Plan [Member] \| Taiwan [Member]
Pension Benefits
Defined Benefit Plan, Contributions by Employer			$ 28

Long-Term Employee Benefits (Schedules of Net Periodic Benefit Cost) (Details) - Netherlands and Taiwan [Member] - Foreign Pension Plan [Member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 3	$ 6
Interest cost	4	9
Expected return on plan assets	(20)	(41)
Amortization of loss (gain)	3	7
Amortization of prior service cost (benefit)	1	2
Net periodic benefit cost	$ (9)	$ (17)

Long-Term Employee Benefits (Assumptions) (Details)	6 Months Ended
Long-Term Employee Benefits (Assumptions) (Details)	Jun. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.00%
Rate of compensation increase	4.00%
Foreign Pension Plan [Member] \| Netherlands and Taiwan [Member]
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.00%
Expected return on plan assets	7.00%
Rate of compensation increase	4.00%

Long-Term Employee Benefits (Plan Assets) (Details) - Foreign Pension Plan [Member] $ in Millions	Jan. 01, 2015 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$ 1,201
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	43
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$ 1,158
Netherlands and Taiwan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations	100.00%
Defined Benefit Plan, Fair Value of Plan Liabilities	$ (17)
Defined Benefit Plan, Fair Value of Plan Assets, Net of Plan Liabilities	$ 1,184
Netherlands and Taiwan [Member] \| U.S. Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations	22.00%
Netherlands and Taiwan [Member] \| Non U.S. Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations	20.00%
Netherlands and Taiwan [Member] \| Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations	58.00%
Netherlands and Taiwan [Member] \| US Treasury and Government [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$ 523
Netherlands and Taiwan [Member] \| US Treasury and Government [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0
Netherlands and Taiwan [Member] \| US Treasury and Government [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	523
Netherlands and Taiwan [Member] \| Corporate Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	136
Netherlands and Taiwan [Member] \| Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	43
Netherlands and Taiwan [Member] \| Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	93
Netherlands and Taiwan [Member] \| Asset-backed Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	35
Netherlands and Taiwan [Member] \| Asset-backed Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0
Netherlands and Taiwan [Member] \| Asset-backed Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	35
Netherlands and Taiwan [Member] \| Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	486
Netherlands and Taiwan [Member] \| Equity Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0
Netherlands and Taiwan [Member] \| Equity Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	486
Netherlands and Taiwan [Member] \| Derivatives Financial Instruments, Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	33
Netherlands and Taiwan [Member] \| Derivatives Financial Instruments, Assets [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0
Netherlands and Taiwan [Member] \| Derivatives Financial Instruments, Assets [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	33
Netherlands and Taiwan [Member] \| Derivative Financial Instruments, Liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	(12)
Netherlands and Taiwan [Member] \| Derivative Financial Instruments, Liabilities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0
Netherlands and Taiwan [Member] \| Derivative Financial Instruments, Liabilities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$ (12)

Long-Term Employee Benefits (Cash Flow) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Parent Company [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$ 52,000,000
Defined Contribution Plan, Employer Discretionary Contribution, Percent of Employees' Gross Pay	3.00%
Defined Contribution Plan, Employer Discretionary Contribution, Years of Service to Vest	3 years
United States Pension Plan of US Entity [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer		$ 0
United States Pension Plan of US Entity [Member] \| Parent Company [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Contributions in Current Fiscal Year	$ 15,000,000
Foreign Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plans, Estimated Future Employer Contributions in Current Fiscal Year	5,000,000
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
Remainder of 2015	19,000,000
2016	39,000,000
2017	40,000,000
2018	41,000,000
2019	42,000,000
2020-2024	218,000,000
Foreign Pension Plan [Member] \| Parent Company [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer	$ 38,000,000	35,000,000
Other Long-Term Employee Benefit Plans [Member] \| Parent Company [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer		$ 66,000,000

Segment Information (Narrative) (Details)	6 Months Ended
Segment Information (Narrative) (Details)	Jun. 30, 2015 segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment sales	$ 1,508	$ 1,684	$ 2,872	$ 3,255
Less: Transfers	0	2	1	4
Net sales	1,508	1,682	2,871	3,251
Adjusted EBITDA	127	235	272	436
Depreciation and amortization	67	64	131	128
Corporate, Non-Segment [Member]
Segment sales	0	0	0	0
Less: Transfers	0	0	0	0
Net sales	0	0	0	0
Adjusted EBITDA	(41)	(60)	(79)	(120)
Depreciation and amortization	0	0	0	0
Titanium Technologies [Member] \| Operating Segments [Member]
Segment sales	642	788	1,188	1,499
Less: Transfers	0	2	1	4
Net sales	642	786	1,187	1,495
Adjusted EBITDA	95	210	194	390
Depreciation and amortization	32	31	63	61
Fluoroproducts [Member] \| Operating Segments [Member]
Segment sales	588	601	1,140	1,180
Less: Transfers	0	0	0	0
Net sales	588	601	1,140	1,180
Adjusted EBITDA	66	77	147	151
Depreciation and amortization	21	21	42	43
Chemical Solutions [Member] \| Operating Segments [Member]
Segment sales	278	295	544	576
Less: Transfers	0	0	0	0
Net sales	278	295	544	576
Adjusted EBITDA	7	8	10	15
Depreciation and amortization	$ 14	$ 12	$ 26	$ 24

Segment Information (Reconciliation to Consolidated Income Statements) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting [Abstract]
Total segment adjusted EBITDA	$ 127	$ 235	$ 272	$ 436
Interest	(28)	0	(28)	0
Depreciation and amortization	(67)	(64)	(131)	(128)
Non-operating pension and other postretirement employee benefit costs	(8)	(10)	(15)	(15)
Exchange gains (losses)	19	5	3	4
Restructuring charges	(61)	(20)	(61)	(21)
Gains (losses) on sale of business or assets	0	9	0	11
(Loss) income before income taxes	$ (18)	$ 155	$ 40	$ 287

Subsequent Events (Details) - Scenario, Forecast [Member] - Replacement Equity Awards [Member] $ in Millions	3 Months Ended
	Sep. 30, 2015 USD ($)
Subsequent Event [Line Items]
Allocated Share-based Compensation Expense	$ 6
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized	$ 18